- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00528944
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
July 2, 2015 updated by: Columbia University
Although single breath helium (He) dilution measurement (VASB) is currently used in pulmonary function laboratories to assess functional alveolar volume and diffusing capacity for carbon monoxide, the extent to which VASB reflects ventilatory and thoracic volume has not been prospectively determined in emphysema.
We hypothesized that VASB underestimates rebreathe helium dilution volume (VARB), and plethysmographic volume (VApleth) as clinical and physiologic severity of emphysema increases.
Study Overview
Status
Completed
Conditions
Detailed Description
VASB, VARB, and VApleth were measured in 52 consecutive stable outpatients with clinical and radiographic emphysema.
Thirteen patients with an obstructive ventilatory defect without emphysema (OVD) and 18 normal controls were similarly studied.
All subjects underwent spirometry followed by whole body plethysmography and He dilution volume measurements; VASB and VARB order was randomized.
Study Type
Observational
Enrollment (Actual)
73
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
NY, New York, United States, 10032
- Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 81 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This is a prospective trial in all outpatients with emphysema referred for full pulmonary function testing to the pulmonary diagnostic unit.
Description
Inclusion Criteria:
- All outpatients between the ages of 18 and 81 years referred to the Columbia University Medical Center Pulmonary Diagnostic Unit between 1/18/06 and 7/30/07 for full pulmonary function evaluation, and with an obstructive ventilatory defect on spirometry, were considered eligible.
Exclusion Criteria:
- Patients who did not want to undergo the re-breathe diffusing capacity testing
- Patients who could not give informed consent;and
- Patients who were too physically compromised to undergo full testing including the re-breathe maneuver as deemed by our technicians.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Cohort A
Patients with obstructive defects and radiological evidence of emphysema
|
|
Cohort B
Patients with obstructive ventilatory defects and no radiological evidence of emphysema
|
|
Cohort C
Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference between DLCO SB alveolar volume and the total lung volume measurement from plethysmography
Time Frame: 10 seconds
|
To test the hypothesis that DLCO SB underestimates DLCO derived by the re-breathe DLCO maneuver, and that VA SB similarly underestimates VA RB.
Alveolar volume derived with the two maneuvers will be compared with body plethysmography, the gold standard of total lung volume measurement in patients with emphysema.
|
10 seconds
|
|
Difference between DLCO RB alveolar volume and the total lung volume measurement from plethysmography
Time Frame: 10 seconds
|
To test the hypothesis that DLCO SB underestimates DLCO derived by the re-breathe DLCO maneuver, and that VA SB similarly underestimates VA RB.
Alveolar volume derived with the two maneuvers will be compared with body plethysmography, the gold standard of total lung volume measurement in patients with emphysema.
|
10 seconds
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert C Basner, MD, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
September 11, 2007
First Submitted That Met QC Criteria
September 12, 2007
First Posted (Estimate)
September 14, 2007
Study Record Updates
Last Update Posted (Estimate)
July 7, 2015
Last Update Submitted That Met QC Criteria
July 2, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAB6328
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonaryUnited States, Australia, Austria, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
Aeris TherapeuticsCompleted
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
Rabin Medical CenterUnknownPatients With Advanced Homogeneous EmphysemaIsrael
-
Aeris TherapeuticsWithdrawnAdvanced Upper Lobe Predominant Emphysema